» Authors » Simon P Harding

Simon P Harding

Explore the profile of Simon P Harding including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 84
Citations 2953
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Hernandez C, Simo-Servat O, Porta M, Grauslund J, Harding S, Frydkjaer-Olsen U, et al.
Acta Diabetol . 2023 Mar; 60(6):837-844. PMID: 36959506
Aims: Neurodegeneration and glial activation are primary events in the pathogenesis of diabetic retinopathy. Serum glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) are biomarkers of underlying neuroinflammatory...
2.
Akil H, Burgess J, Nevitt S, Harding S, Alam U, Burgess P
Diabetes Ther . 2021 Dec; 13(1):1-23. PMID: 34928488
To systematically review the epidemiology of early worsening of diabetic retinopathy (EWDR) after substantial improvements in glycaemic control and evaluate characteristics including risk factors. This systematic review was registered with...
3.
Hykin P, Prevost A, Sivaprasad S, Vasconcelos J, Murphy C, Kelly J, et al.
Health Technol Assess . 2021 Jun; 25(38):1-196. PMID: 34132192
Background: Licensed ranibizumab (0.5 mg/0.05 ml Lucentis; Novartis International AG, Basel, Switzerland) and aflibercept (2 mg/0.05 ml Eylea; Bayer AG, Leverkusen, Germany) and unlicensed bevacizumab (1.25 mg/0.05 ml Avastin; F....
4.
Georgiadou A, Naidu P, Walsh S, Kamiza S, Barrera V, Harding S, et al.
Clin Transl Immunology . 2021 May; 10(4):e1263. PMID: 33968402
Objective: Cerebral malaria (CM) is a complication of malaria, in which progressive brain swelling is associated with sequestration of parasites and impaired barrier function of the cerebral microvascular endothelium. To...
5.
Romdhoniyyah D, Harding S, Cheyne C, Beare N
Ophthalmol Ther . 2021 Apr; 10(2):245-260. PMID: 33846958
Background: Currently, no generally approved medical treatment can delay the onset of age-related macular degeneration (AMD) or slow the progression of degenerative changes. Repurposing drugs with beneficial effects on AMD...
6.
Cheyne C, Burgess P, Broadbent D, Garcia-Finana M, Stratton I, Criddle T, et al.
Diabet Med . 2021 Apr; 38(9):e14583. PMID: 33830513
Aims: Systematic annual screening to detect sight-threatening diabetic retinopathy (STDR) is established in the United Kingdom. We designed an observational cohort study to provide up-to-date data for policy makers and...
7.
Broadbent D, Wang A, Cheyne C, James M, Lathe J, Stratton I, et al.
Diabetologia . 2020 Nov; 64(1):56-69. PMID: 33146763
Aims/hypothesis: Using variable diabetic retinopathy screening intervals, informed by personal risk levels, offers improved engagement of people with diabetes and reallocation of resources to high-risk groups, while addressing the increasing...
8.
MacCormick I, Barrera V, Beare N, Czanner G, Potchen M, Kampondeni S, et al.
J Infect Dis . 2020 Aug; 225(6):1070-1080. PMID: 32845969
Background: In cerebral malaria, the retina can be used to understand disease pathogenesis. The mechanisms linking sequestration, brain swelling, and death remain poorly understood. We hypothesized that retinal vascular leakage...
9.
Evans R, Reeves B, Phillips D, Muldrew K, Rogers C, Harding S, et al.
Ophthalmology . 2020 May; 127(9):1191-1200. PMID: 32359843
Purpose: To describe visual outcomes, frequency of treatment and monitoring visits, and anti-vascular endothelial growth factor drugs used in usual care in participants who exited a trial in which treatment...
10.
Hernandez C, Porta M, Bandello F, Grauslund J, Harding S, Aldington S, et al.
J Clin Med . 2020 Apr; 9(4). PMID: 32344735
The main aim of this study was to evaluate the ability of serum biomarkers to predict the worsening of retinal neurodysfunction in subjects with type 2 diabetes. For this purpose,...